Endovascular surgeries combined with EPCs agonists, such as EPO and SDF-1α, have demonstrated promise in enhancing endothelialization and reducing aneurysm recanalization (Liu et al., 2016a,b; Yu et al., 2019). The gene discussed is CXCL12; the disease is aneurysm.